172 related articles for article (PubMed ID: 34337142)
1. ExoHCR: a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis.
Hu L; Chen W; Zhou S; Zhu G
Biophys Rep; 2020 Dec; 6(6):290-298. PubMed ID: 34337142
[TBL] [Abstract][Full Text] [Related]
2. Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling.
Wang C; Huang CH; Gao Z; Shen J; He J; MacLachlan A; Ma C; Chang Y; Yang W; Cai Y; Lou Y; Dai S; Chen W; Li F; Chen P
ACS Sens; 2021 Sep; 6(9):3308-3319. PubMed ID: 34494426
[TBL] [Abstract][Full Text] [Related]
3. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
4. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.
Wen X; Zeng X; Cheng X; Zeng X; Liu J; Zhang Y; Li Y; Chen H; Huang J; Guo Z; Chen X; Zhang X
Mol Pharm; 2022 Oct; 19(10):3612-3622. PubMed ID: 35652897
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.
Rasihashemi SZ; Rezazadeh Gavgani E; Majidazar R; Seraji P; Oladghaffari M; Kazemi T; Lotfinejad P
J Cell Physiol; 2022 Mar; 237(3):1648-1660. PubMed ID: 34825383
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer cells synergistically defend against CD8
Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B
Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of PD-L1
Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
[TBL] [Abstract][Full Text] [Related]
9. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
12. The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer.
Tang Y; Zhang P; Wang Y; Wang J; Su M; Wang Y; Zhou L; Zhou J; Xiong W; Zeng Z; Zhou Y; Nie S; Liao Q
Front Immunol; 2020; 11():604. PubMed ID: 32322256
[TBL] [Abstract][Full Text] [Related]
13. Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment.
Zheng J; Huang J; Zhang L; Wang M; Xu L; Dou X; Leng X; Fang M; Sun Y; Wang Z
Biomater Res; 2023 Feb; 27(1):9. PubMed ID: 36759928
[TBL] [Abstract][Full Text] [Related]
14. [Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung Cancer].
Wang N; Song X
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice.
Garcia MG; Deng Y; Murray C; Reyes RM; Padron A; Bai H; Kancharla A; Gupta H; Shen-Orr S; Curiel TJ
Aging Cancer; 2022 Mar; 3(1):68-83. PubMed ID: 36876140
[TBL] [Abstract][Full Text] [Related]
16. Single-Step and Highly Sensitive Imaging of Exosomal PD-L1 through Aptamer-Activated Cascade Primer Exchange Reaction-Generated Branched DNA Nanostructures.
Li X; Li X; Cheng X; Bian X; Shen B; Ding X; Ding S
ACS Sens; 2022 Nov; 7(11):3571-3579. PubMed ID: 36329604
[TBL] [Abstract][Full Text] [Related]
17. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
19. Identification of programmed death ligand-1 positive exosomes in breast cancer based on DNA amplification-responsive metal-organic frameworks.
Cao Y; Wang Y; Yu X; Jiang X; Li G; Zhao J
Biosens Bioelectron; 2020 Oct; 166():112452. PubMed ID: 32738648
[TBL] [Abstract][Full Text] [Related]
20. Serum-derived exosomes promote CD8+ T cells to overexpress PD-1, affecting the prognosis of hypopharyngeal carcinoma.
Gao Q; Liu HT; Xu YQ; Zhang L; Liu YR; Ren Q; Sheng JP; Zhang ZX
Cancer Cell Int; 2021 Oct; 21(1):584. PubMed ID: 34717645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
